The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole

British Journal of Clinical Pharmacology

Volumn 57, Issue 6, 2004, Pages 773-784

  Sobue, Satoshi ^a   Tan, Keith ^b   Layton, Gary ^b   Leclerc, Violette ^c   Weil, Angelika ^d  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c Aster Clinical Research Center   (France)

^d APEX GmbH   (Germany)

Author keywords

Fluconazole; Fosfluconazole; Pharmacokinetics; Renal impairment; Safety

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; FOSFLUCONAZOLE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; SIDE EFFECT;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; FEMALE; FLUCONAZOLE; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; MALE; PHOSPHORIC ACID ESTERS;

EID: 2942542634     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02073.x     Document Type: Article

References (36)

1. Phillips P, De Beule K, Frechette G et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis 1998; 26: 1368-73.
2. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 662-78.
3. Jacobs LG, Skidmore EA, Freeman K, Lipschultz D, Fox N. Oral fluconazole compared with bladder irrigation with amphotericin B for treatment of fungal urinary tract infections in elderly patients. Clin Infect Dis 1996; 22: 30-5.
4. Levine J, Bernard DB, Idelson BA, Farnham H, Saunders C, Sugar AM. Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: successful treatment with fluconazole, a new orally active antifungal agent. Am J Med 1989; 86: 825-7.
5. Anaissie EJ, Darouiche RO, Abi-Said D et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23: 964-72.
6. Anaissie E, Bodey GP, Kantarjian H et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991; 91: 142-50.
7. Flanagan PG, Barnes RA. Hazards of inadequate fluconazole dosage to treat deep-seated or systemic Candida albicans infection. J Infect 1997; 35: 295-7.
8. Ikemoto H. A clinical study of fluconazole for the treatment of deep mycoses. Diagn Microbiol Infect Dis 1989; 12 (Suppl. 4): S239-S247.
9. Van't Wout JW, Mattie H, van Furth R. A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. J Antimicrob Chemother 1988; 21: 665-72.
10. Goa KL, Barradell LB. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50: 658-90.
11. Troke PF. Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. Multicentre European Study Group. Eur J Clin Microbiol Infect Dis 1997; 16: 287-95.
12. Brammer KW. Management of fungal infection in neutropenic patients with fluconazole. Haematol Blood Transfus 1990; 33: 546-50.
13. Ikemoto H, Watanabe K, Mori T et al. Clinical study of fluconazole on deep-seated fungal infections. Jpn J Antibiot 1989; 42: 63-116.
14. Maruta A, Matsuzaki M, Fukawa H, Kodama F. Clinical evaluation of fluconazole in the case of deep mycosis associated with leukemia. Jpn J Antibiot 1989; 42: 117-26.
15. Toyama K, Lin KY, Hojo H, Tsuda A, Torii Y, Yoshikawa O. A clinical evaluation of injectable fluconazole in the treatment of deep mycosis associated with hematological malignancy. Jpn J Antibiot 1989; 42: 47-54.
16. Lee Y, Shiota T, Ikeda S et al. Clinical efficacy of fluconazole in the patient with pulmonary mycosis. Jpn J Antibiot 1989; 42: 138-43.
17. Nito H. Clinical efficacy of fluconazole in urinary tract fungal infections. Jpn J Antibiot 1989; 42: 171-8.
18. Saag MS, Powderly WG, Cloud GA et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326: 83-9.
19. Yamaguchi H, Ikemoto H, Watanabe K, Ito A, Hara K, Kohno S. Fluconazole monotherapy for cryptococcosis in non-AIDS patients. Eur J Clin Microbiol Infect Dis 1996; 15: 787-92.
20. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12 (Suppl. 3): S318-S326.
21. Toon S, Ross CE, Gokal R, Rowland M. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol 1990; 29: 221-6.
22. Berl T, Wilner KD, Gardner M et al. Pharmacokinetics of fluconazole in renal failure. J Am Soc Nephrol 1995; 6: 242-7.
23. Bentley A, Butters M, Green SP et al. The discovery and process development of a commercial route to the water soluble prodrug, fosfluconazole. Org Process Res Dev 2002; 6: 109-12.
24. Fernley HN. Mammalian alkaline phosphatases. In The Enzymes, 3rd edn, ed Boyer PD. New York and London: Academic Press, 1971; 417-47.
25. Nouwen EJ, De Broe ME. Human intestinal versus tissue-nonspecific alkaline phosphatase as complementary urinary markers for the proximal tubule. Kidney Int 1994; 46 (Suppl. 47): S43-S51.
26. Guder WG, Ross BD. Enzyme distribution along the nephron. Kidney Int 1984; 26: 101-11.
27. Sobue S, Sekiguchi K, Shimatani K, Tan K. Pharmacokinetics and safety of fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers. J Clin Pharmacol 2004; 44: 284-92.
28. Garrow JS, Webster J. Quetelet's index (W/H2) as a measure of fatness. Int J Obes 1985; 9: 147-53.
29. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
30. SAS Institute Inc. SAS/SAT Users Guide, Version 6.09, 4th edn. Cary, NC: SAS Institute Inc., 1994.
31. Pesola GR, Akhavan I, Madu A, Shah NK, Carlon GC. Prediction equation estimates of creatinine clearance in the intensive care unit. Intensive Care Med 1993; 19: 39-43.
32. O'Connell MB, Dwinell AM, Bannick-Mohrland SD. Predictive performance of equations to estimate creatinine clearance in hospitalized elderly patients. Ann Pharmacother 1992; 26: 627-35.
33. Lam NP, Sperelakis R, Kuk J, Seeger JD, Lau AH. Rapid estimation of creatinine clearances in patients with liver dysfunction. Dig Dis Sci 1999; 44: 1222-7.
34. Nawaratne S, Brien JE, Seeman E et al. Relationships among liver and kidney volumes, lean body mass and drug clearance. Br J Clin Pharmacol 1998; 46: 447-52.
35. Sobue S, Tan K, Layton G, Eve M, Sanderson JB. Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers. Br J Clin Pharmacol in press.
36. Aweeka FT, Gottwald MD, Gambertoglio JG et al. Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia 1999; 40: 777-82.